Amitriptyline

Generic Name: Amitriptyline

Brand Names: Elavil

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₃N

CAS Number: 50-48-6

Unique Ingredient Identifier: 1806D8D52K

Background: Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.

Indication: This drug in indicated for the following conditions :

Major depressive disorder in adults

Management of neuropathic pain in adults

Prophylactic treatment of chronic tension-type headache (CTTH) in adults

Prophylactic treatment of migraine in adults
...

Associated Conditions: Anorexia Nervosa (AN), Attention Deficit Hyperactivity Disorder (ADHD), Bulimia Nervosa, Depression, Depression Acute, Diabetic Neuropathies, Insomnia, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Migraine, Moderate Depression, Neuropathic Pain, Nocturnal Enuresis, Severe Depression, Sleep disorders and disturbances, Tension Headache, Moderate Agitation, Moderate Anxiety, Severe Anxiety, Severe agitation

Associated Therapies: -

Clinical Trials

Amitriptyline or Pregabalin to Treat Neuropathic Pain in Incurable Cancer

Phase 3

Conditions: Cancer
Neuralgia

Interventions: Drug: pregabalin
Drug: amitriptyline

First Posted Date: 2008-08-25

Last Posted Date: 2009-02-05

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 130

Registration Number: NCT00740571

Locations: 🇳🇱
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands
🇳🇱
VUMC, Amsterdam, Noord-Holland, Netherlands

Study of Medication for Functional Abdominal Pain in Children

Phase 4

Completed

Conditions: Functional Gastrointestinal Disorders

Interventions: Drug: Amitriptyline
Drug: Placebo

First Posted Date: 2007-11-28

Last Posted Date: 2007-11-28

Lead Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago

Target Recruit Count: 95

Registration Number: NCT00564525

Locations: 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States

Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo

Phase 2

Completed

Conditions: Cystic Fibrosis
Infection
Pseudomonas Aeruginosa

Interventions: Drug: amitriptyline

First Posted Date: 2007-08-13

Last Posted Date: 2007-08-13

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 18

Registration Number: NCT00515229

Locations: 🇩🇪
University of Tuebingen, Tuebingen, Baden-Wuerttemberg, Germany

Pediatric Chronic Headache Trial

Phase 3

Conditions: Headache

Interventions: Behavioral: Coping Skills Training
Behavioral: Headache Education
Drug: Amitriptyline

First Posted Date: 2006-10-17

Last Posted Date: 2011-04-25

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 132

Registration Number: NCT00389038

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Mail Location 3015, Cincinnati, Ohio, United States

Effects of Pregabalin, Duloxetine & Amitriptyline on Pain & Sleep

Phase 2

Completed

Conditions: Diabetes Mellitus
Peripheral Neuropathies

First Posted Date: 2006-09-01

Last Posted Date: 2009-11-17

Lead Sponsor: University of Surrey

Target Recruit Count: 90

Registration Number: NCT00370656

Locations: 🇬🇧
Poole General Hospital, Poole, Dorset, United Kingdom
🇬🇧
Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
🇬🇧
University of Surrey Clinical Research Centre, Guildford, Surrey, United Kingdom

Local Anaesthetic Effects of Transcutaneous Amitriptyline

Phase 1

Completed

Conditions: Healthy Volunteers

First Posted Date: 2006-07-21

Last Posted Date: 2013-04-04

Lead Sponsor: University Hospital, Clermont-Ferrand

Target Recruit Count: 16

Registration Number: NCT00355277

Locations: 🇫🇷
Centre de Pharmacologie Clinique /Cic, Clermont-ferrand, Auvergne, France

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2006-07-13

Last Posted Date: 2011-01-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 494

Registration Number: NCT00351910

Locations: 🇸🇪
Research Site, Uppsala, Sweden

Comparing Gabapentin and Amitriptyline for the Treatment of Neuropathic Pain in Children and Adolescents

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Gabapentin
Drug: Amitriptyline

First Posted Date: 2006-04-07

Last Posted Date: 2020-10-20

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 34

Registration Number: NCT00312260

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Functional Dyspepsia Treatment Trial

Phase 2

Completed

Conditions: Dyspepsia and Other Specified Disorders of Function of Stomach

Interventions: Drug: Placebo
Drug: Amitriptyline
Drug: Escitalopram

First Posted Date: 2005-11-04

Last Posted Date: 2014-07-25

Lead Sponsor: Mayo Clinic

Target Recruit Count: 292

Registration Number: NCT00248651

Locations: 🇺🇸
Northwestern University Chicago, Chicago, Illinois, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 4 locations

Tricyclic Antidepressants (TCAs) on Gastric Emptying

Not Applicable

Terminated

Conditions: Dyspepsia

Interventions: Drug: Amitriptyline
Drug: Desipramine

First Posted Date: 2005-09-22

Last Posted Date: 2021-03-05

Lead Sponsor: Temple University

Target Recruit Count: 10

Registration Number: NCT00220844

Locations: 🇺🇸
Temple University School of Medicine, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy